Devoted Health Expands Medicare Advantage Coverage for CVRx's Barostim Therapy — CVRx, Inc.

Event summary

Devoted Health issued a Medicare Advantage coverage policy for CVRx's Barostim therapy, effective July 17, 2026.
The policy covers Barostim for FDA-approved indications and patients in the BENEFIT-HF trial.
Devoted Health's coverage, combined with Humana's, represents ~21% of Medicare Advantage enrollment.
This follows other 2026 reimbursement milestones, including CPT codes and CMS IDE coverage for BENEFIT-HF.

The big picture

This coverage expansion reflects growing payer acceptance of neuromodulation therapies for heart failure, a market where reimbursement consistency has been a historical challenge. The inclusion of BENEFIT-HF trial patients suggests payers are anticipating expanded indications based on emerging clinical evidence. With ~21% of Medicare Advantage members now covered, CVRx appears to be making progress in its strategy to achieve more uniform reimbursement.

What we're watching

Coverage Expansion: Whether CVRx can secure similar policies from other major Medicare Advantage providers to further expand access.
Clinical Trial Progress: The pace at which the BENEFIT-HF trial delivers results that could support broader FDA approval.
Reimbursement Dynamics: How the combination of CPT codes, CMS coverage, and private payer policies impacts Barostim's commercial adoption.